| 參考文獻 |
[1] R. C. Gallo et al., "Frequent detection and isolation of cytopathic retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS," science, vol. 224, no. 4648, pp. 500-503, 1984.
[2] I. Muñoz-Arias, G. Doitsh, Z. Yang, S. Sowinski, D. Ruelas, and W. C. Greene, "Blood-derived CD4 T cells naturally resist pyroptosis during abortive HIV-1 infection," Cell host & microbe, vol. 18, no. 4, pp. 463-470, 2015.
[3] D. R. Burton and J. R. Mascola, "Antibody responses to envelope glycoproteins in HIV-1 infection," Nature immunology, vol. 16, no. 6, pp. 571-576, 2015.
[4] S. Stahlman et al., "Characterizing the HIV risks and potential pathways to HIV infection among transgender women in Cote d′Ivoire, Togo and Burkina Faso," Journal of the International AIDS Society, vol. 19, no. 3S2, p. 20774, 2016.
[5] C. Cicala, J. Arthos, and A. S. Fauci, "Role of T-cell trafficking in the pathogenesis of HIV disease," Current Opinion in HIV and AIDS, vol. 14, no. 2, pp. 115-120, 2019.
[6] V. Wacleche, C. Tremblay, J.-P. Routy, and P. Ancuta, "The biology of monocytes and dendritic cells: contribution to HIV pathogenesis," Viruses, vol. 10, no. 2, p. 65, 2018.
[7] I. K. Craig, X. Xia, and J. W. Venter, "Introducing HIV/AIDS education into the electrical engineering curriculum at the University of Pretoria," IEEE Transactions on Education, vol. 47, no. 1, pp. 65-73, 2004.
[8] D. Mondal, "Zidovudine (azidothymidine AZT)," in Reference Module in Biomedical Sciences: Elsevier, 2016.
[9] W. E. Diederich and H. Steuber, Therapy of Viral Infections. Berlin Heidelberg: Springer, 2015.
[10] R. Aguilar-López, R. V. Gómez-Acata, G. Lara-Cisneros, and R. Femat, "Nonlinear and robust control strategy based on chemotherapy to minimize the HIV concentration in blood plasma," Journal of Control Science and Engineering, vol. 2016, pp. 1-6, 2016.
[11] R. D. Moore and R. E. Chaisson, "Natural history of HIV infection in the_era of combination antiretroviral therapy," Aids, vol. 13, no. 14, pp. 1933-1942, 1999.
[12] E. S. Rosenberg et al., "Vigorous HIV-1-specific CD4+T cell responses associated with control of viremia," Science, vol. 278, no. 5342, pp. 1447-1450, 1997.
[13] W. C. Greene et al., "Novel targets for HIV therapy," Antiviral research, vol. 80, no. 3, pp. 251-265, 2008.
[14] F. Clavel and A. J. Hance, "HIV drug resistance," New England Journal of Medicine, vol. 350, no. 10, pp. 1023-1035, 2004.
[15] Q. D. Pham, D. P. Wilson, M. G. Law, A. D. Kelleher, and L. Zhang, "Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis," Aids, vol. 28, no. 18, pp. 2751-2762, 2014.
[16] K. C. Behrens G, Schedel I, Mendila M, Schmidt RE., "Highly active antiretroviral therapy," Lancet, vol. 351, no. 9108, pp. 1056–1057, 1998.
[17] J. Lou, Y. Lou, and J. Wu, "Threshold virus dynamics with impulsive antiretroviral drug effects," Journal of Mathematical Biology, vol. 65, no. 4, pp. 623-652, 2012.
[18] M. K. Symon Chibaya, Estomih S. Massawe, "Mathematical analysis of drug resistance in vertical transmission of HIV/AIDS," Open Journal of Epidemiology, vol. 3, no. 3, pp. 139–148, 2013.
[19] H. Chang and A. Astolfi, "Enhancement of the immune system in HIV dynamics by output feedback," Automatica, vol. 45, no. 7, pp. 1765-1770, 2009.
[20] I. Cremin, R. Alsallaq, M. Dybul, P. Piot, G. Garnett, and T. B. Hallett, "The new role of antiretrovirals in combination HIV prevention: a mathematical modelling analysis," Aids, vol. 27, no. 3, pp. 447-458, 2013.
[21] H. Shim, N. H. Jo, H. Chang, and J. H. Seo, "A system theoretic study on a treatment of AIDS patient by achieving long-term non-progressor," Automatica, vol. 45, no. 3, pp. 611-622, 2009.
[22] D. Kirschner, S. Lenhart, and S. Serbin, "Optimal control of the chemotherapy of HIV," Journal of mathematical biology, vol. 35, no. 7, pp. 775-792, 1997.
[23] H. Chang and A. Astolfi, "Control of HIV infection dynamics," IEEE Control Systems, vol. 28, no. 2, pp. 28-39, 2008.
[24] H. Chang and A. Astolfi, "Activation of immune response in disease dynamics via controlled drug scheduling," IEEE Transactions on Automation Science and Engineering, vol. 6, no. 2, pp. 248-255, 2009.
[25] R. Zurakowski and A. R. Teel, "Enhancing immune response to HIV infection using MPC-based treatment scheduling," in American Control Conference, Denver, CO, USA, 2003, vol. 2, pp. 1182-1187.
[26] R. Zurakowski and A. R. Teel, "A model predictive control based scheduling method for HIV therapy," Journal of Theoretical Biology, vol. 238, no. 2, pp. 368-382, 2006.
[27] S. S. Ge, Z. Tian, and T. H. Lee, "Nonlinear control of a dynamic model of HIV-1," IEEE Transactions on Biomedical Engineering, vol. 52, no. 3, pp. 353-361, 2005.
[28] S. S. Ge and J. Wang, "Robust adaptive tracking for time-varying uncertain nonlinear systems with unknown control coefficients," IEEE Transactions on Automatic Control, vol. 48, no. 8, pp. 1463-1469, 2003.
[29] C. G. Wang, S. S., "Adaptive backstepping control of uncertain lorenz system," International Journal of Bifurcation and Chaos, vol. 11, no. 4, pp. 1115-1119, 2001.
[30] H. N. Pishkenari and A. Meghdari, "Adaptive backstepping control of uncertain Lorenz system," in 5th International Symposium on Mechatronics and Its Applications, Amman, Jordan, 2008, pp. 1-6.
[31] M. A. Melgarejo, C. A. Pena-Reyes, and E. Sanchez, "A Genetic-Fuzzy system approach to control a model of the HIV infection dynamics," in IEEE International Conference on Fuzzy Systems, Vancouver, BC, Canada, 2006, pp. 2323-2330.
[32] D. U. Campos-Delgado and E. Palacios, "Non-linear Observer for the Estimation of CD8 Count Under HIV-1 Infection," in 2007 American Control Conference, New York, NY, USA, 2007, pp. 4101-4105.
[33] M. E. Brandt and G. Chen, "Feedback control of a biodynamical model of HIV-1," IEEE Transactions on Biomedical Engineering, vol. 48, no. 7, pp. 754-759, 2001.
[34] W. Assawinchaichote, "Control of HIV/AIDS infection system with drug dosages design via robust H∞ fuzzy controller," Bio-Medical Materials and Engineering, vol. 26, no. s1, pp. 1945-1951, 2015.
[35] W. Assawinchaichote, "Control of Dynamic HIV/AIDS Infection System with Robust H∞ Fuzzy Output Feedback Controller," International Journal of Modeling and Optimization, vol. 3, no. 3, pp. 293-297, 2013.
[36] C. Y. Ho and B. W. Ling, "Initiation of HIV therapy," International Journal of Bifurcation and Chaos, vol. 20, no. 04, pp. 1279-1292, 2010.
[37] M. A. Nowak and R. M. May, Virus dynamics: mathematical principles of immunology and virology. Oxford Oxford University Press, 2000.
[38] A. Korobeinikov, "Global properties of basic virus dynamics models," Bulletin of Mathematical Biology, vol. 66, no. 4, pp. 879-883, 2004.
[39] J. H. Ko, W. H. Kim, and C. C. Chung, "Optimized structured treatment interruption for HIV therapy and its performance analysis on controllability," IEEE Transactions on Biomedical Engineering, vol. 53, no. 3, pp. 380-386, 2006.
[40] V. Radisavljevic-Gajic, "Optimal control of HIV-virus dynamics," Annals of Biomedical Engineering, vol. 37, no. 6, pp. 1251-1261, 2009.
[41] G. Pannocchia, M. Laurino, and A. Landi, "A model predictive control strategy toward optimal structured treatment interruptions in anti-HIV therapy," IEEE Transactions on Biomedical Engineering, vol. 57, no. 5, pp. 1040-1050, 2010.
[42] H. Zarei, A. V. Kamyad, and M. H. Farahi, "Optimal control of HIV dynamic using embedding method," Computational and mathematical methods in medicine, vol. 2011, pp. 1-9, 2011.
[43] X. Xia, "Estimation of HIV/AIDS parameters," Automatica, vol. 39, no. 11, pp. 1983-1988, 2003.
[44] N. H. Jo and Y. Roh, "A two-loop robust controller fyor HIV infection models in the presence of parameter uncertainties," Biomedical Signal Processing and Control, vol. 18, pp. 245-253, 2015.
[45] P. S. Rivadeneira, M. Caicedo, A. Ferramosca, and A. H. Gonzalez, "Impulsive zone model predictive control (IZMPC) for therapeutic treatments: application to HIV dynamics," in IEEE Conference on Decision and Control, Melbourne, VIC, Australia, 2017, pp. 4094-4099.
[46] J. Zhai, J. Kim, K. S. Knox, R. H. Twigg, H. Zhou, and J. J. Zhou, "Variance component selection with applications to microbiome taxonomic data," Frontiers in Microbiology, vol. 9, pp. 509-525, 2018.
[47] P. D. Giamberardino and D. Iacoviello, "HIV Infection Control: A Constructive Algorithm for a State-based Switching Control," International Journal of Control Automation and Systems, vol. 16, no. 3, pp. 1469-1473, 2018.
[48] R. K. Spooner et al., "Aberrant oscillatory dynamics during somatosensory processing in HIV-infected adults," NeuroImage-Clinical, vol. 20, pp. 85-91, 2018.
[49] E. Palacios, G. Espinosa-Perez, and D. U. Campos-Delgado, "A passivity-based approach for HIV-1 treatment scheduling," in 2007 American Control Conference, New York, NY, USA, 2007, pp. 4106-4111.
[50] X. Wang, X. Liu, W. Xu, and K. Zhang, "Stochastic dynamics of HIV models with switching parameters and pulse control," Journal of the Franklin Institute, vol. 352, no. 7, pp. 2765-2782, 2015.
[51] J. A. Moreno, G. Espinosa–Pérez, and E. Palacios, "A robust output-feedback treatment scheduling for HIV-1," IFAC Proceedings Volumes, vol. 40, no. 4, pp. 169-174, 2007.
[52] A. Azizi, "Control of HIV/AIDS infection system with reverse transcriptase inhibitors dosages design via robust feedback controller," Biosensors Journal, vol. 6, no. 146, pp. 1-6, 2017.
[53] WHO. "Global hepatitis report," April 2017. [Online]. Available: https://www.who.int/hepatitis/publications/global-hepatitis-report2017/en/
[54] A. P. Kourtis, B. Marc, D. J. Hu, and D. J. Jamieson, "HIV-HBV coinfection--a global challenge," New England Journal of Medicine, vol. 366, no. 19, pp. 1749-52, 2012.
[55] C. Long, H. Qi, and S. H. Huang, "Mathematical modeling of cytotoxic lymphocyte-mediated immune response to hepatitis B virus infection," Journal of Biomedicine and Biotechnology, vol. 2008, no. 1, pp. 1-9, 2008.
[56] H. Nampala, L. S. Luboobi, J. Y. T. Mugisha, C. Obua, and M. Jablonska-Sabuka, "Modelling hepatotoxicity and antiretroviral therapeutic effect in HIV/HBV coinfection," Mathematical Biosciences, vol. 302, pp. 67-79, 2018.
[57] M. Puoti, D. Manno, P. Nasta, and G. Carosi, "Hepatitis B virus and HIV coinfection in low-income countries: unmet needs," Clinical Infectious Diseases, vol. 46, no. 3, pp. 367-369, 2008.
[58] B. Buonomo and C. Vargas-De-León, "Global stability for an HIV-1 infection model including an eclipse stage of infected cells," Journal of Mathematical Analysis and Applications, vol. 385, no. 2, pp. 709-720, 2012.
[59] A. S. Perelson, "Modelling viral and immune system dynamics," Nature Reviews Immunology, vol. 2, no. 1, pp. 28-36, 2002.
[60] S. Haitao, J. Weihua, and L. Shengqiang, "Virus dynamics model with intracellular delays and immune response," Mathematical Biosciences and Engineering, vol. 12, no. 1, pp. 185-208, 2017.
[61] K. Murai et al., "Mathematical modeling of porcine epidemic diarrhea virus dynamics within a farrow-to-finish swine farm to investigate the effects of control measures," Preventive Veterinary Medicine, vol. 149, pp. 115-124, 2018.
[62] A. S. Perelson and P. W. Nelson, "Mathematical analysis of HIV-1 dynamics in vivo," SIAM review vol. 41, no. 1, pp. 3-44, 1999.
[63] V. Reinharz, H. Dahari, and D. Barash, "Numerical schemes for solving and optimizing multiscale models with age of hepatitis C virus dynamics," Mathematical Biosciences, vol. 300, pp. 1-13, 2018.
[64] M. A. Nowak, S. Bonhoeffer, A. M. Hill, R. Boehme, H. C. Thomas, and H. McDade, "Viral dynamics in hepatitis B virus infection," Proceedings of the National Academy of Sciences of the United States of America, vol. 93, no. 9, pp. 4398-4402, 1996.
[65] X. Chen, L. Min, Y. Ye, and Y. Zheng, "Modeling and simulation for dynamics of anti-HBV infection therapy," in Advances in Automation and Robotics, vol. 2, Berlin, Heidelberg: Springer, 2011, pp. 557-566.
[66] X. Chen, K. Sun, J. Qiu, X. Chen, C. Yang, and A. Zhang, "Dynamics analysis of an amended HBV infection model with a simulation for anti-HBV infection therapy," in Proceedings of the 33rd Chinese Control Conference, Nanjing, China, 2014, pp. 2829-2834.
[67] X. Chen, J. Qiu, W. Qin, T. Li, and C. Yang, "Modeling and simulation for dynamics of tenofovir disoproxil fumarate anti-HBV infection therapy," in 2017 Chinese Automation Congress (CAC), Jinan, China, 2017, pp. 7307-7310.
[68] X. Chen, L. Q. Min, and Q. L. Sun, "Dynamics analysis and numerical simulation of an amended HBV infection model," Journal of Biomathematics, vol. 28, no. 2, pp. 278-284, 2013.
[69] L. Min and Y. Ye, "A Mathematical model of the dynamics for anti-HBV infection therapy with chinese herbs+adefovir dipivoxi," in 2009 3rd International Conference on Bioinformatics and Biomedical Engineering, Beijing, China, 2009, pp. 1-4.
[70] Z. Guo, Z. Hong, and Q. Xie, "A mathematical model for anti-HBV infection combination therapy with peginterferon alfa-2a and lamivudine," in 2010 4th International Conference on Bioinformatics and Biomedical Engineering, Chengdu, Sichuan, 2010, pp. 1-4.
[71] X. Song and A. U. Neumann, "Global stability and periodic solution of the viral dynamics," Journal of Mathematical Analysis and Applications, vol. 329, no. 1, pp. 281-297, 2007.
[72] D. Rocha, C. J. Silva, and D. F. M. Torres, "Stability and optimal control of a delayed HIV model," Mathematical Methods in the Applied Sciences, vol. 41, no. 6, pp. 2251-2260, 2018.
[73] P. Chanprasopchai, I. M. Tang, and P. Pongsumpun, "SIR model for dengue disease with effect of dengue vaccination," Computational and Mathematical Methods in Medicine, vol. 2018, pp. 1-14, 2018.
[74] X. Wang and J. Lou, "Two dynamic models about rabies between dogs and human," Journal of Biological Systems, vol. 16, no. 4, pp. 519-529, 2008.
[75] J. Zhang, Z. Jin, G.-Q. Sun, T. Zhou, and S. Ruan, "Analysis of rabies in China: transmission dynamics and control," PLoS One, vol. 6, no. 7, p. e20891, 2011.
[76] P. D. Giamberardino and D. Iacoviello, "HIV infection control: a constructive algorithm for a state-based switching control," International Journal of Control Automation and Systems, vol. 16, no. 3, pp. 1469–1473, 2018.
[77] N. H. Jo and Y. Roh, "A two-loop robust controller for HIV infection models in the presence of parameter uncertainties," Biomedical Signal Processing and Control, vol. 18, pp. 245-253, 2015.
[78] M. J. Mhawej, C. H. Moog, F. Biafore, and C. Brunet-François, "Control of the HIV infection and drug dosage," Biomedical Signal Processing and Control, vol. 5, no. 1, pp. 45-52, 2010.
[79] P. K. Roy, Mathematical models for therapeutic approaches to control HIV disease transmission. Singapore: Springer, 2015.
[80] J. A. Lewnard and Y. H. Grad, "Vaccine waning and mumps re-emergence in the United States," Science translational medicine, vol. 10, no. 433, p. eaao5945, 2018.
[81] F. M. C. de Souza, "Modeling the dynamics of HIV-1 and CD4 and CD8 lymphocytes," IEEE Engineering in Medicine and Biology Magazine, vol. 18, no. 1, pp. 21-24, 1999.
[82] R. Salpini et al., "Combination of HBV serological markers can predict the burden and productivity of intrahepatic HBV reservoir and disease progression in HBeAg-negative chronic hepatitis B infection," Digestive and Liver Disease, vol. 50, no. 1, p. 13, 2018.
[83] K. Wang, G. Jiang, Z. Jia, X. Zhu, and C. Ni, "Effects of transarterial chemoembolization combined with antiviral therapy on HBV reactivation and liver function in HBV-related hepatocellular carcinoma patients with HBV-DNA negative," Medicine, vol. 97, no. 22, pp. 1-4, 2018.
[84] J. Gong and X. Liu, "Effect of HBIG combined with hepatitis B vaccine on blocking HBV transmission between mother and infant and its effect on immune cells," Experimental and Therapeutic Medicine, vol. 15, no. 1, pp. 919-923, 2018.
[85] D. Sun and F. Liu, "Modeling and control of a delayed hepatitis B virus model with incubation period and combination treatment," Interdisciplinary Sciences Computational Life Sciences, vol. 10, no. 2, pp. 375-389, 2018.
[86] D. Wu and Q. Ning, "Combination therapy," in Hepatitis B Virus and Liver Disease: Springer Singapore, 2018, pp. 219-237.
[87] H. K. Khalil and J. W. Grizzle, Nonlinear systems. Prentice hall Upper Saddle River, NJ, 2002.
[88] A. Bacciotti and L. Rosier, Liapunov functions and stability in control theory. Springer Science & Business Media, 2006.
[89] Z. Shen et al., "Effects of CD4 cell counts and viral load testing on mortality rates in patients with HIV infection receiving antiretroviral treatment: an observational cohort study in rural southwest China," Clinical Infectious Diseases, vol. 63, no. 1, pp. 108-114, 2016.
[90] M. S. Saag et al., "HIV viral load markers in clinical practice," Nature Medicine, vol. 2, no. 6, pp. 625-629, 1996.
[91] D. Muir, D. White, J. King, N. Verlander, and D. Pillay, "Predictive value of the ultrasensitive HIV viral load assay in clinical practice," Journal of Medical Virology, vol. 61, no. 4, pp. 411-416, 2015.
[92] K. Kamalanand and P. M. Jawahar, "Prediction of human immunodeficiency virus-1 viral load from CD4 cell count using artificial neural networks," Journal of Medical Imaging and Health Informatics, vol. 5, no. 3, pp. 641-646, 2015.
[93] K. Kamalanand and P. M. Jawahar, "Comparison of swarm intelligence techniques for estimation of HIV-1 viral load," Iete Technical Review, vol. 32, no. 3, pp. 188-195, 2015.
[94] P. K. Balne et al., "Dataset of longitudinal analysis of tear cytokine levels, CD4, CD8 counts and HIV viral load in dry eye patients with HIV infection," Data in Brief, vol. 11, no. C, pp. 152-154, 2017.
[95] T. Peter et al., "Scaling up HIV viral load-lessons from the large-scale implementation of HIV early infant diagnosis and CD4 testing," Journal of the International Aids Society, vol. 20, no. S7, pp. 9-15, 2017.
[96] Z. Bentwich, "CD4 measurements in patients with HIV: Are they feasible for poor settings?," Plos Medicine, vol. 2, no. 7, pp. 595-596, 2005.
[97] Y. Ding and W.-J. Wang, "Switching control strategy for the HIV dynamic system with some unknown parameters," IET systems biology, vol. 13, no. 1, pp. 30-35, 2018.
[98] J. A. Owen, J. Punt, and S. A. Stranford, Kuby immunology. New York, NY, USA: WH Freeman, 2013.
[99] H. O. Charlotte Yuk-Fan and W. K. Ling, "Initiation of HIV therapy," International Journal of Bifurcation and Chaos, vol. 20, no. 04, pp. 1279-1292, 2010.
[100] E. A. Waters, T. Pachur, and G. A. Colditz, "Side effect perceptions and their impact on treatment decisions in women," Medical Decision Making, vol. 37, no. 3, pp. 193-203, 2017.
[101] B. Buonomo and C. Vargas-De-León, "Global stability for an HIV-1 infection model including an eclipse stage of infected cells," Journal of Mathematical Analysis & Applications, vol. 385, no. 2, pp. 709-720, 2012.
[102] L. Rong, M. A. Gilchrist, Z. Feng, and A. S. Perelson, "Modeling within-host HIV-1 dynamics and the evolution of drug resistance: Trade-offs between viral enzyme function and drug susceptibility," Journal of Theoretical Biology, vol. 247, no. 4, pp. 804-818, 2007.
[103] Q. Sun, L. Min, and Y. Kuang, "Global stability of infection-free state and endemic infection state of a modified human immunodeficiency virus infection model," IET Systems Biology, vol. 9, no. 3, pp. 95-103, 2015.
[104] A. Perasso, "An introduction to the basic reproduction number in mathematical epidemiology," ESAIM: Proceedings and Surveys, vol. 62, pp. 123-138, 2018.
[105] J. M. Orellana, "Optimal drug scheduling for HIV therapy efficiency improvement," Biomedical Signal Processing and Control, vol. 6, no. 4, pp. 379-386, 2011.
[106] B. Christine, H. Zhenyue, R. Klaus, A. J. Potocnik, and S. Brigitta, "Ablation of thymic export causes accelerated decay of naive CD4 T cells in the periphery because of activation by environmental antigen," Proceedings of the National Academy of Sciences, vol. 105, no. 25, pp. 8691-8696, 2008.
[107] R. F. Vogel, M. Becke-Schmid, P. Entgens, W. Gaier, and W. P. Hammes, "Laboratory control values for CD4 and CD8 T lymphocytes implications for HIV-1 diagnosis," Clinical & Experimental Immunology, vol. 88, no. 2, pp. 243-252, 2010.
[108] Y. Wang, Y. Zhou, J. Wu, and J. Heffernan, "Oscillatory viral dynamics in a delayed HIV pathogenesis model," Mathematical Biosciences, vol. 219, no. 2, pp. 104-112, 2009.
[109] P. A. Netland, Glaucoma medical therapy: principles and management. Oxford University Press, USA, 2008.
[110] W. Kaplan and R. Laing, "Fixed dose combinations as an innovative delivery mechanism," Priority Mechanisms for Europe and the World: A Public Health Approach to Innovation, Oct. 2004. [Online] Available: http://archives.who.int/prioritymeds/report/background/delivery.doc
[111] J. H. Jones, "Notes on Ro," Department of Anthropological Sciences, Stanford University, Califonia, pp. 1-19, 2007.
[112] C. Nakul, "Introduction to mathematical epidemiology: the basic reproductive number," Einfuhrung in die Mathematische Epidemiologie, p. 5, 2011.
[113] J. A. P. Heesterbeek and K. Dietz, "The concept of Ro in epidemic theory," Statistica Neerlandica, vol. 50, no. 1, pp. 89-110, 2010.
[114] L. Min, Y. Su, and Y. Kuang, "Mathematical analysis of a basic virus infection model with application to HBV infection," Rocky Mountain Journal of Mathematics, vol. 38, no. 5, pp. 1573-1585, 2008.
[115] Y. Zheng, L. Min, Y. Ji, Y. Su, and Y. Kuang, "Global stability of endemic equilibrium point of basic virus infection model with application to HBV infection," Journal of Systems Science and Complexity, vol. 23, no. 6, pp. 1221-1230, 2010.
[116] M. Nowak and R. M. May, Virus dynamics: mathematical principles of immunology and virology. Oxford Oxford university press, 2000.
[117] O. Sharomi, C. N. Podder, A. B. Gumel, S. M. Mahmud, and E. Rubinstein, "Modelling the transmission dynamics and control of the novel 2009 swine influenza (H1N1) pandemic," Bulletin of Mathematical Biology, vol. 73, no. 3, pp. 515-548, 2011.
[118] S. Shan, F. Cui, and J. Jia, "How to control highly endemic hepatitis B in Asia," Liver International, vol. 38, no. S1, pp. 122-125, 2018.
[119] C. Béguelin et al., "Hepatitis delta-associated mortality in HIV/HBV-coinfected patients," Journal of hepatology, vol. 66, no. 2, pp. 297-303, 2017.
[120] W. C. Tsai et al., "Impact of antiretroviral therapy containing tenofovir disoproxil fumarate on the survival of patients with HBV and HIV coinfection," Liver International, 2019.
[121] Z. Min and X. Yong, "A time-periodic dengue fever model in a heterogeneous environment," Mathematics and Computers in Simulation, p. S0378475417304007, 2018.
[122] M. Cabrera and G. Taylor, "Modelling spatio-temporal data of dengue fever using generalized additive mixed models," Spatial and spatio-temporal epidemiology, vol. 28, pp. 1-13, 2019.
[123] J. J. Tewa, J. L. Dimi, and S. Bowong, "Lyapunov functions for a dengue disease transmission model," Chaos Solitons and Fractals, vol. 39, no. 2, pp. 936-941, 2009.
|
[Endnote RIS 格式]
[相關文章]
[文章引用]
[完整記錄]
[館藏目錄]
[檢視]
plurk
funp
live
udn
HD
myshare
netvibes
friend
youpush
delicious
baidu
Google bookmarks
del.icio.us
hemidemi
facebook
twitter
google
reddit